Journal
CLINICAL INFECTIOUS DISEASES
Volume 73, Issue 9, Pages E3120-E3123Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa1804
Keywords
severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2); seroprevalence; coronavirus disease 2019 (COVID-19); convenience sampling
Categories
Funding
- Centers for Disease Control and Prevention, Atlanta, GA
Ask authors/readers for more resources
The study compared seroprevalence estimates from commercial laboratory residual sera and a community household survey in metropolitan Atlanta, finding the two estimates to be similar (4.94% vs 3.18%). Commercial sera can provide a rough measure of seroprevalence compared to more representative surveys.
We compared severe acute respiratory syndrome coronavirus 2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April and May 2020 and found these 2 estimates to be similar (4.94% vs 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available